Unexo's Operations Questioned as FDA Lists 12 Compliance Issues

Unexo, an over-the-counter drug manufacturer, faced FDA scrutiny during an inspection from May 1 to May 14, 2024. Investigators Nicole Knowlton and Kellia Hicks led the inspection, which resulted in a Warning Letter covering everything from inadequate documentation to improper facility maintenance. This breakdown covers the key observations and what they mean for Unexo's operations and reputation.

What were the 12 compliance issues identified during Unexo's FDA inspection?

In a detailed review of Unexo's facility, FDA investigators identified serious shortcomings in regulatory compliance. The inspection, which lasted two weeks, culminated in a Form 483 report outlining 12 significant issues that raised questions about the company's manufacturing standards and operational practices. These findings have drawn attention to potential risks associated with Unexo's products and its commitment to quality.

Let's take a closer look at the FDA's observations:

1. Machine Usage Records Are Misleading

The Human-Machine Interface (HMI) indicated the last usage of key equipment was on April 21, 2024, marking the end of a production run. However, supporting batch records were missing, raising questions about its data integrity and record-keeping practices.

2. Inadequate Performance Qualification (PQ) Practices

• Unexo failed to produce a batch record supporting the performance qualification (PQ) of Machine P1, documented in its March 2022 report.
• Only two production runs were conducted during the PQ, lacking justification for this limited scope.
• Key operating parameters and equipment limits were not verified, undermining the credibility of their PQ process.

3. Facility Maintenance Issues

During a walkthrough on May 3, 2024, investigators discovered a hole in the ceiling of the In-Process Quality Assurance (IPQA) area, exposing HVAC ducting. This poses risks to product quality and contaminates the manufacturing environment.

4. Uncontrolled Access to Labeling Materials

Investigators noted unrestricted access to the storage area for labels and packaging materials. Labels in various stages of usage were found without proper lot numbers or quantity markings, a lapse that compromises traceability and control.

5. Lack of Detailed Written Procedures

Unexo lacked written procedures detailing the handling, storage, and testing of drug components, containers, and closures. Investigators observed bins of finished products stored haphazardly, undermining product integrity.

Atlas

See what the FDA knows about your next investigator.

700,000+ inspections since 2010. Search by investigator, CFR code, or supplier. Every 483 they’ve issued, in under a second.

See it live

6. Missing Lot Codes and Expiry Details

Numerous finished drug products in the production and storage areas lacked lot codes or expiration dates. Firm personnel were unable to identify the batches in question, a major lapse in traceability.

7. Inadequate In-Process Controls

The FDA found Unexo's in-process validation protocols insufficient. Sampling schemes lacked statistical rigor, and key parameters during validation didn't match those in production records.

8. Disorganized Batch Records

Investigators found inconsistencies between the parameters listed in batch records and those in validation reports. For example, temperature and pressure settings used during validation were not reflected in production documentation.

9. Improper Documentation Practices

In the batch coding area, investigators found assorted items, including incomplete cleaning records and packaging materials without lot codes or expiration dates. This reflects poor document management practices.

10. Lack of Verification for Equipment Limits

Unexo failed to update equipment specifications or verify critical manufacturing parameters. This oversight compromises the reproducibility and quality of their drug products.

11. Compromised Storage Practices

Investigators observed bins of drug products stored without proper identification or status labeling. This lack of organization increases the risk of mix-ups and quality failures.

12. Deficient Process Validation Protocols

Unexo's process validation reports lacked sufficient sampling and failed to ensure consistent manufacturing quality. These deficiencies cast doubt on their ability to produce compliant drug products.

What This Means for Unexo

The findings indicate systemic issues in its manufacturing processes, documentation practices, and facility maintenance. Non-compliance with FDA regulations not only jeopardizes product quality but also risks patient safety and brand reputation.

Addressing these observations requires a comprehensive overhaul of its quality systems. Immediate corrective and preventive actions (CAPAs) must focus on:

1. Strengthening documentation and traceability.
2. Conducting thorough validations with comprehensive sampling.
3. Ensuring facilities meet Good Manufacturing Practices (GMP).
4. Training personnel to uphold regulatory standards.

Unexo's response will determine its ability to restore FDA confidence and maintain market credibility. Inadequate documentation and improper facility maintenance put the company's operations and reputation at risk. Atlas helps quality teams avoid these pitfalls by giving them access to 700,000+ FDA inspections since 2010, including 30,000+ Form 483s and EIRs, 11,828 warning letters, and 6,000+ investigator reports. Teams can study how similar observations were handled, benchmark their CAPAs, and prepare for the investigators assigned to their site before the inspection happens.

With the issuance of a warning letter, it's imperative for Unexo to meticulously review and strengthen its compliance measures. Each step towards addressing these issues is crucial to avoid further regulatory actions and prevent potential operational and reputational losses.

Stay tuned as we monitor Unexo's next steps and their impact on the industry.